P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials
This study sought to investigate the efficacy and safety of P2Y12 inhibitor monotherapy compared with conventional dual antiplatelet therapy (DAPT) and aspirin monotherapy in patients with ACS undergoing percutaneous coronary intervention. Data on 4,453 patients were pooled from SMART-DATE and SMART-CHOICE randomized trials. Antiplatelet therapy regimens were categorized as P2Y12 inhibitor monotherapy (P2Y12 inhibitor monotherapy after 3-month DAPT), conventional DAPT (12-month or longer DAPT), and aspirin monotherapy (aspirin monotherapy after 6-month DAPT).
Source: The American Journal of Cardiology - Category: Cardiology Authors: Pil Sang Song, Yong Hwan Park, Ju-Hyeon Oh, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Deok-Kyu Cho, Seung-Woon Rha, Jang-Whan Bae, Jin-Ok Jeong, Joo-Yong Hahn, for the SMART-DATE and the SMART-CHOICE investigators Source Type: research
More News: Angioplasty | Aspirin | Cardiology | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Study